Sonoma Pharmaceu Stock Price, News & Analysis

Sonoma Pharmaceuticals (SNOA) reported Q1 2022 revenues of $3.7 million, down 36% from $5.8 million in Q1 2021, primarily due to reduced sales in Latin America following the termination of its Invekra contract. Gross profit remained stable at 39%. Operating expenses decreased by 19% to $2.4 million, yet the net loss increased 55% to $1.1 million, attributed to previous business unit sales. Despite challenges, the transition to a distribution model aims to improve profitability for its prescription products. As of June 30, 2021, Sonoma held $2.8 million in cash.

Sonoma Pharmaceuticals (SNOA) reported its fiscal year 2021 and Q4 results, showing a total revenue of $2.2 million for the quarter, declining 50% year-over-year, attributed to a $1.6 million drop in U.S. dermatology sales and revenue adjustments. Annual revenue reached $18.6 million, up 4% from the previous year. Sonoma's operating expenses decreased by 49% in Q4, totaling $2.6 million, mainly due to reduced headcount and manufacturing consolidation. However, the net loss widened to $3.6 million for the quarter, a 111% increase. The company continues to focus on strategic partnerships and international expansion.

Sonoma Pharmaceuticals (Nasdaq: SNOA) has entered a five-year agreement with EMC Pharma to exclusively manage, market, and distribute its HOCl-based dermatology and eye care products in the U.S. EMC Pharma will also distribute certain Microcyn-based wound care products in government channels. The partnership aims to reduce Sonoma's overhead from its unprofitable direct sales model while expanding its distribution network. EMC will acquire existing inventory and adhere to minimum purchase requirements to maintain exclusivity.

Sonoma Pharmaceuticals, a leader in hypochlorous acid products for healthcare, has announced CEO Amy Trombly and CFO Jerry Dvonch will present at two virtual conferences: the H.C. Wainwright Global Life Sciences Conference from March 9-10, 2021, and the Maxim Emerging Growth Conference from March 17-18, 2021. Both presentations will be available on demand. Investors interested in meetings with management can contact the respective conference coordinators. Sonoma's products address various health issues and are available in 54 countries.

Sonoma Pharmaceuticals (Nasdaq: SNOA) reported a 12% revenue increase to $4.94 million for Q3 FY2020, driven by sales growth in Latin America and Europe, despite a decline in U.S. revenue due to COVID-19. Operating expenses decreased by 31% to $2.13 million, primarily from headcount reductions and facility closures. The net loss from continuing operations improved to $626,000 compared to $1.21 million in Q3 FY2019. Over nine months, revenue rose 21% to $16.47 million, although gross margins decreased to 41%. Sonoma's cash reserves increased to $5.44 million, signifying improved liquidity.

Sonoma Pharmaceuticals (Nasdaq: SNOA) announces that its Dermodacyn® disinfectant has received import clearance as a medical device for Thailand. This product, which has shown effectiveness against SARS-CoV-2, is now available in pharmacies and online in Hong Kong and Thailand. Dermodacyn is designed for disinfecting areas that may harbor harmful bacteria and viruses, with safety for human use being a key feature. Sonoma's CEO stated plans for ongoing research and development to expand product offerings.

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) announced that CEO Amy Trombly and CFO Jerry Dvonch will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference from January 11-14, 2021. The presentation will be available on-demand starting at 6:00 AM ET on January 11. Registration for the presentation can be accessed here. The company specializes in stabilized hypochlorous acid products for various healthcare applications.

Sonoma Pharmaceuticals (Nasdaq: SNOA) has entered into a non-exclusive distribution agreement with Gabriel Science, LLC to market its Microcyn® Technology products in the dental sector, receiving its first order.

Endocyn®, a product in this line, is a biocompatible root canal irrigant shown to have lower cellular toxicity than traditional irrigants in a study by Louisiana State University. The partnership aims to enhance Sonoma's market presence in dental healthcare, promoting advanced treatment options for dental conditions.